Small molecule tyrosine kinase inhibitors in pancreatic cancer

Sachin Gupta, Bassel F El-RayesDepartment of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University, MI, USAAbstract: Pancreatic cancer has proven to be chemo-resistant, with gemcitabine being the only cytotoxic agent approved for advanced pancreatic cancer since 1996. Tyrosine kinas...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sachin Gupta, Bassel F El-Rayes
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/bc8f52d5ed4b4a968040fa9cc7351cdc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bc8f52d5ed4b4a968040fa9cc7351cdc
record_format	dspace
spelling	oai:doaj.org-article:bc8f52d5ed4b4a968040fa9cc7351cdc2021-12-02T01:12:59ZSmall molecule tyrosine kinase inhibitors in pancreatic cancer1177-54751177-5491https://doaj.org/article/bc8f52d5ed4b4a968040fa9cc7351cdc2008-10-01T00:00:00Zhttp://www.dovepress.com/small-molecule-tyrosine-kinase-inhibitors-in-pancreatic-cancer-a2376https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Sachin Gupta, Bassel F El-RayesDepartment of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University, MI, USAAbstract: Pancreatic cancer has proven to be chemo-resistant, with gemcitabine being the only cytotoxic agent approved for advanced pancreatic cancer since 1996. Tyrosine kinase inhibitors represent a newer generation of chemotherapeutic agents targeting specific tumor pathways associated with carcinogenesis including cell cycle control, signal transduction, apoptosis and angiogenesis. These agents present a more selective way of treating pancreatic cancer. Erlotinib is the prototype of the tyrosine kinase inhibitors with proven efficacy in advanced pancreatic cancer and has been recently approved in that setting. Multiple other tyrosine kinase inhibitors targeting the VEGFR, PDGFR, and Src kinases are in various phases of clinical trials testing. The preliminary results of these trials have been disappointing. Current challenges in pancreatic cancer clinical trials testing include improving patient selection, identifying effective combinations, improving the predictive value of current preclinical models and better study designs. This review summarizes the present clinical development of tyrosine kinase inhibitors in pancreatic cancer and strategies for future drug development.Keywords: pancreatic cancer, erlotinib, tyrosine kinase inhibitors Sachin GuptaBassel F El-RayesDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 4, Pp 707-715 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Sachin Gupta Bassel F El-Rayes Small molecule tyrosine kinase inhibitors in pancreatic cancer
description	Sachin Gupta, Bassel F El-RayesDepartment of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University, MI, USAAbstract: Pancreatic cancer has proven to be chemo-resistant, with gemcitabine being the only cytotoxic agent approved for advanced pancreatic cancer since 1996. Tyrosine kinase inhibitors represent a newer generation of chemotherapeutic agents targeting specific tumor pathways associated with carcinogenesis including cell cycle control, signal transduction, apoptosis and angiogenesis. These agents present a more selective way of treating pancreatic cancer. Erlotinib is the prototype of the tyrosine kinase inhibitors with proven efficacy in advanced pancreatic cancer and has been recently approved in that setting. Multiple other tyrosine kinase inhibitors targeting the VEGFR, PDGFR, and Src kinases are in various phases of clinical trials testing. The preliminary results of these trials have been disappointing. Current challenges in pancreatic cancer clinical trials testing include improving patient selection, identifying effective combinations, improving the predictive value of current preclinical models and better study designs. This review summarizes the present clinical development of tyrosine kinase inhibitors in pancreatic cancer and strategies for future drug development.Keywords: pancreatic cancer, erlotinib, tyrosine kinase inhibitors
format	article
author	Sachin Gupta Bassel F El-Rayes
author_facet	Sachin Gupta Bassel F El-Rayes
author_sort	Sachin Gupta
title	Small molecule tyrosine kinase inhibitors in pancreatic cancer
title_short	Small molecule tyrosine kinase inhibitors in pancreatic cancer
title_full	Small molecule tyrosine kinase inhibitors in pancreatic cancer
title_fullStr	Small molecule tyrosine kinase inhibitors in pancreatic cancer
title_full_unstemmed	Small molecule tyrosine kinase inhibitors in pancreatic cancer
title_sort	small molecule tyrosine kinase inhibitors in pancreatic cancer
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/bc8f52d5ed4b4a968040fa9cc7351cdc
work_keys_str_mv	AT sachingupta smallmoleculetyrosinekinaseinhibitorsinpancreaticcancer AT basselfelrayes smallmoleculetyrosinekinaseinhibitorsinpancreaticcancer
_version_	1718403221536374784

Small molecule tyrosine kinase inhibitors in pancreatic cancer

Ejemplares similares